



September 27, 2024

To,
Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
BSE Scrip Code: 544029

Listing & Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor
Plot No. C/1, “G” Block
Bandra-Kurla Complex
Bandra (E), Mumbai – 400 051
Symbol: GANDHAR

Dear Sir/Madam,

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food & Drug Administration (USFDA) had inspected Company’s manufacturing facility located at Taloja. The inspection was conducted from September 23, 2024 to September 27, 2024. On conclusion of the inspection, the Company received 2 (Two) observations in Form 483.

We are addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe.

You are requested to kindly take the same on record.

Thanking You,

Yours Faithfully

For **Gandhar Oil Refinery (India) Limited**

Jayshree Soni
Company Secretary and Compliance Officer
Mem. No.: FCS 6528